Semax Preserves Neuron Count and Boosts PGC-1α in Rat Model of Ischemic Stroke
Background
The pharmacological activation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) is a promising but underdeveloped strategy for neuroprotection after an ischemic stroke. PGC-1α is a key regulator of ischemic brain tolerance, influencing processes like mitochondriogenesis, angiogenesis, and synaptogenesis. Following a stroke, PGC-1α expression is typically suppressed in the penumbra (the at-risk tissue surrounding the core infarct), contributing to ongoing neuronal damage. However, there are very few pharmacological agents known to reliably modulate cerebral PGC-1α activity. This study investigates two potential candidates, Mexidol and the peptide Semax, to see if they can counteract this post-stroke suppression and activate this critical neuroprotective pathway.
Study Design
This study used a rat model of photochemical-induced thrombosis (PT) in the prefrontal cortex to simulate an ischemic stroke. One group of rats received intranasal Semax (25 μg/kg), and another received intraperitoneal Mexidol (100 mg/kg). Both treatments were administered for 7 days. Researchers measured the expression of PGC-1α and related protein markers for mitochondriogenesis, angiogenesis, and synaptogenesis in the penumbra (the ischemic boundary zone) at days 1, 3, 7, and 21 post-stroke using immunoblotting. The nuclear content of PGC-1α was assessed using immunohistochemistry to determine its activation and translocation.
Results
The study found a significant and prolonged suppression of PGC-1α expression in the penumbra of untreated rats, lasting from 24 hours to 21 days after the induced stroke. This suppression was linked to both a decrease in the total number of surviving neurons and reduced PGC-1α expression within individual neurons. In contrast, rats treated with either Semax or Mexidol showed significant neuroprotective effects.
Both compounds were associated with the preservation of neuron numbers in the penumbra and maintained higher neuronal expression of
PGC-1α.
Furthermore, Semax and Mexidol stimulated the nuclear translocation of PGC-1α, a key step in its activation. This activation led to increased levels of downstream protein markers associated with PGC-1α-dependent pathways, including mitochondriogenesis, angiogenesis, and synaptogenesis. These findings demonstrate that both Semax and Mexidol can effectively counteract the post-stroke suppression of the neuroprotective PGC-1α system.
Key Findings
- Ischemic stroke suppressed PGC-1α expression in the rat penumbra for up to 21 days.
- Daily administration of Semax (25 μg/kg, intranasal) for 7 days preserved the number of neurons post-stroke.
- Semax treatment maintained neuronal PGC-1α expression, counteracting the stroke-induced suppression.
- Semax stimulated the nuclear translocation of PGC-1α, indicating its activation.
- Treatment increased protein markers for PGC-1α-dependent mitochondriogenesis, angiogenesis, and synaptogenesis.
Why It Matters
This research identifies Semax as a potent pharmacological activator of the PGC-1α pathway in the context of ischemic brain injury. For individuals exploring neuroprotective agents, this provides a specific mechanism for Semax's reported benefits, positioning it as a tool to support mitochondrial health, blood vessel formation, and synaptic plasticity after an ischemic event. While this is an animal study, the findings are significant because they open new avenues for developing treatments that specifically target PGC-1α to improve stroke outcomes. The key takeaway is that Semax may not only preserve neurons but actively promote recovery pathways that are normally suppressed after a stroke. This suggests its potential utility in post-stroke recovery protocols, although human trials are needed to confirm dosage, timing, and efficacy. The intranasal route of administration is also noteworthy for its direct brain-targeting potential.
TitrateLab articles covering Semax
Written by TitrateLab, separately from the study summarized above.
semax
mexidol
stroke
ischemia
neuroprotection
pgc-1α
